NCT00809835 is a Phase 2 clinical trial of Galantamine in Cocaine Dependence, sponsored by Yale University.

Who is sponsoring NCT00809835?

NCT00809835 is sponsored by Yale University.

What drugs are being tested in NCT00809835?

Interventions in NCT00809835: Galantamine, Computer Assisted Cognitive Behavioral Therapy (CBT).

What condition does NCT00809835 study?

NCT00809835 studies Cocaine Dependence.

Is NCT00809835 still recruiting?

NCT00809835 is currently completed. Last updated 28 January 2019.

Are results published for NCT00809835?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-01-28 · How we verify

NCT00809835

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse With Methadone Maintained Individuals

Completed Phase 2 Results posted Last updated 28 January 2019

What this trial tests

Phase 2 trial testing Galantamine in Cocaine Dependence in 120 participants. Completed in 1 January 2015.

Timeline

1 December 2007

Primary endpoint
1 January 2015

1 January 2015

Quick facts

Lead sponsor	Yale University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	double
Primary purpose	treatment
Enrollment	120
Start date	1 December 2007
Primary completion	1 January 2015
Estimated completion	1 January 2015
Sites	2 locations across United States

Drugs / interventions tested

Galantamine (GALANTAMINE) — full drug profile →
Computer Assisted Cognitive Behavioral Therapy (CBT)

Conditions studied

Cocaine Dependence — all drugs for Cocaine Dependence →

Sponsor

Yale University

Who can join

Adults 18 to 50, any sex, with Cocaine Dependence. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Cocaine Use
Time frame: 12 weeks
Reduction in cocaine use, operationalized as the frequency of cocaine use by month using timeline followback.
Cocaine Abstinence
Time frame: 12 weeks
operationalized by percentage of drug-free urine specimens submitted (We will use the Branan ToxCup Drug Screen Cup onsite TESTCUP system for detection of cocaine, methamphetamine, THC, benzodiazepine, and opioids) at 12 Weeks

Sponsor's own description

We are testing to see if Galantamine, a learning enhancing medication, will help methadone maintained cocaine abusers with their learning and memory specific to CBT using an innovative CBT computer program.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Dissociable neural substrates of opioid and cocaine use identified via connectome-based modelling.
Lichenstein SD, Scheinost D, Potenza MN, Carroll KM, et al · · 2021 · cited 70× · PMID 31719641 · DOI 10.1038/s41380-019-0586-y
Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial.
Carroll KM, Nich C, DeVito EE, Shi JM, et al · · 2018 · cited 48× · PMID 29286595 · DOI 10.4088/jcp.17m11669
Effects of galantamine on cocaine use in chronic cocaine users.
Sofuoglu M, Carroll KM. · · 2011 · cited 23× · PMID 21477060 · DOI 10.1111/j.1521-0391.2011.00130.x

Verify or expand the search:

Other trials of Galantamine

Trials testing the same drug.

NCT07003386 — Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke · Phase 2, PHASE3 · recruiting
NCT04769206 — Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans · Phase 1, PHASE2 · active not recruiting
NCT03384784 — Effect of Galantamine on Inflammation and Cognition · Phase 2 · completed
NCT01677754 — A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy · Phase 2 · completed

Other recruiting trials for Cocaine Dependence

Currently open trials in the same condition.

NCT06189690 — Effect of HF rTMS on Serum BDNF in Cocaine Use Disorder · NA · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00809835 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 28 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00809835.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing